Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study

Clinical Therapeutics

Volumn 31, Issue 2, 2009, Pages 272-285

  Ste Marie, Louis Georges ^a   Brown, Jacques P ^b   Beary, John F ^c   Matzkin, Ellen ^d   Darbie, Lynn M ^c   Burgio, David E ^c   Racewicz, Artur J ^e  

^a UNIVERSITY OF MONTREAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d SANOFI   (France)

^e Centrum Medyczne Specjalistyczny Gabinet Lekarski Bialystok   (Poland)

Author keywords

bone mineral density; bone turnover markers; drug administration schedule; postmenopausal osteoporosis; risedronate

Indexed keywords

RISEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ANXIETY; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEPATITIS; BACKACHE; BILIRUBIN BLOOD LEVEL; BONE DENSITY; BONE TURNOVER; CANADA; CHILL; CLINICAL LABORATORY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROATIA; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENITIS; DYSPEPSIA; ENTEROCOLITIS; ESOPHAGITIS; ETHNICITY; FEMALE; FEVER; FLU LIKE SYNDROME; GASTRITIS; GASTROESOPHAGEAL REFLUX; HOSPITAL; HUMAN; INCIDENCE; LUMBAR SPINE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEURALGIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POLAND; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; STOMATITIS; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 62149096859     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.02.012     Document Type: Article

References (35)

1. National Osteoporosis Foundation. Osteoporosis fast facts [NOF Web site]
2. http://www.nof.org/osteoporosis/diseasefacts.htm Accessed February 22, 2008
3. National Osteoporosis Foundation. Medications to prevent & treat osteoporosis [NOF Web site]
4. http://www.nof.org/patientinfo/medications.htm Accessed January 13, 2009
5. Emkey R.D., and Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 119 Suppl 1 (2006) S18-S24
6. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
7. Cramer J.A., Gold D.T., Silverman S.L., and Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18 (2007) 1023-1031
8. Yood R.A., Emani S., Reed J.I., et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14 (2003) 965-968
9. Eastell R., Garnero P., Vrijens B., et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The IMPACT study. Calcif Tissue Int 72 (2003) 408 Abstract P-297
10. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
11. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
12. Brown J.P., Kendler D.L., McClung M.R., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71 (2002) 103-111
13. Delmas P.D., Benhamou C.L., Man Z., et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: Efficacy and safety results. Osteoporos Int 19 (2008) 1039-1045
14. McClung M.R., Geusens P., Miller P.D., et al., for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
15. US Dept of Health and Human Services. International Conference on Harmonisation; Guidance on General Considerations for Clinical Trials
16. http://www.fda.gov/Cder/Guidance/1857fnl.pdf Accessed September 7, 2008
17. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045
18. World Heath Organization. World Health Organization definitions for osteoporosis [WHO Web site]
19. http://www.bonewellness.com/world_health_organization_osteoporosis.php Accessed January 13, 2009
20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA)
21. http://www.ich.org/cache/compo/276-254-1.html Accessed September 25, 2008
22. In: Burtis C.A., and Ashwood E.R. (Eds). Tietz Textbook of Clinical Chemistry. 3rd ed (1999), WB Saunders, Philadelphia, Pa
23. Fogelman I., Ribot C., Smith R., et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial BMD-MN Study Group. J Clin Endocrinol Metab 85 (2000) 1895-1900
24. Snedecor G.W., and Cochran W.G. Statistical Methods. 8th ed (1989), Iowa State University Press, Ames, Iowa 374-397
25. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo- controlled, parallel-group study. Arthritis Rheum 42 (1999) 2309-2318
26. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15 (2000) 1006-1013
27. Hooper M.J., Ebeling P.R., Roberts A.P., et al. Risedronate prevents bone loss in early postmenopausal women: A prospective randomized, placebo-controlled trial. Climacteric 8 (2005) 251-262
28. Singer F.R., Clemens T.L., Eusebio R.A., and Bekker P.J. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83 (1998) 1906-1910
29. Hosking D.J., Eusebio R.A., and Chines A.A. Paget's disease of bone: Reduction of disease activity with oral risedronate. Bone 22 (1998) 51-55
30. Miller P.D., Brown J.P., Siris E.S., et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med 106 (1999) 513-520
31. Siris E.S., Chines A.A., Altman R.D., et al. Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13 (1998) 1032-1038
32. Brown J.P., Hosking D.J., Ste-Marie L., et al. Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study. Calcif Tissue Int 64 (1999) 93-99
33. Racewicz A.J., Schofield P.J., Cahall D.L., et al. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: A 6-month pilot study. Curr Med Res Opin 23 (2007) 3079-3089
34. Roux C., Seeman E., Eastell R., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20 (2004) 433-439
35. Harrington J.T., Ste-Marie L.G., Brandi M.L., et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74 (2004) 129-135